Document:

Exhibit 10.5

 

FALCON CAPITAL ACQUISITION CORP.

660 Madison Avenue, 12th Floor

New York, NY 10065

 

September 21, 2020

 

Falcon Equity Investors LLC

660 Madison Avenue, 12th Floor

New York, NY 10065

 

Ariliam Group LLC

660 Madison Avenue, 12th Floor

New York, NY 10065

 

Re: Administrative
Services Agreement

 

Ladies and Gentlemen:

 

This letter agreement
(this “Agreement”) by and among Falcon Capital Acquisition Corp. (the “Company”),
Falcon Equity Investors LLC (the “Sponsor”) and Ariliam Group LLC, an affiliate of the Sponsor (“Ariliam
Group”), dated as of the date hereof, will confirm our agreement that, commencing on the date the securities of the
Company are first listed on the Nasdaq Capital Market LLC (the “Listing Date”), pursuant to a Registration
Statement on Form S-1 and prospectus filed with the U.S. Securities and Exchange Commission (the “Registration Statement”)
and continuing until the earlier of the consummation by the Company of an initial business combination or the Company’s liquidation
(in each case as described in the Registration Statement) (such earlier date hereinafter referred to as the “Termination
Date”):

 

1. Ariliam Group shall
make available, or cause to be made available, to the Company, at 660 Madison Avenue, 12th Floor, New York, NY 10065
(or any successor location), office space and secretarial and administrative services as may be reasonably required by the Company.
In exchange therefor, the Company shall pay Ariliam Group $15,000 per month on the Listing Date and continuing monthly thereafter
until the Termination Date; and

 

2. Ariliam Group and
the Sponsor each hereby irrevocably waives any and all right, title, interest, causes of action and claims of any kind as a result
of, or arising out of, this Agreement (each, a “Claim”) in or to, and any and all right to seek payment
of any amounts due to it out of, the trust account established for the benefit of the public stockholders of the Company and into
which substantially all of the proceeds of the Company’s initial public offering will be deposited (the “Trust
Account”), and hereby irrevocably waives any Claim it may have in the future as a result of, or arising out of, this
Agreement, which Claim would reduce, encumber or otherwise adversely affect the Trust Account or any monies or other assets in
the Trust Account, and further agrees not to seek recourse, reimbursement, payment or satisfaction of any Claim against the Trust
Account or any monies or other assets in the Trust Account for any reason whatsoever.

 

This Agreement constitutes
the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes all prior understandings,
agreements, or representations by or between the parties hereto, written or oral, to the extent they relate in any way to the subject
matter hereof or the transactions contemplated hereby.

 

This Agreement may
not be amended, modified or waived as to any particular provision, except by a written instrument executed by the parties hereto.

 

No party hereto may
assign either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the
other party. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer
or assign any interest or title to the purported assignee.

 

This Agreement constitutes
the entire relationship of the parties hereto, and any litigation between the parties (whether grounded in contract, tort, statute,
law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the laws of the State of New York.

 

[Signature Page Follows]

 

     

     

    

 

	 	Very truly yours,
	 	 
	 	FALCON CAPITAL ACQUISITION CORP.
	 	 
	 	By:	/s/ Saif Rahman
	 	 	Name: Saif Rahman
	 	 	Title: Chief Financial Officer

 

	AGREED AND ACCEPTED BY:	 
	 	 
	FALCON EQUITY INVESTORS LLC	 
	 	 
	By: Eagle Falcon JV Co LLC, its managing member	 
	 	 
	By:	/s/ Alan G. Mnuchin	 
	 	Name: Alan G. Mnuchin	 
	 	Title: Managing Member	 
	 	 
	ARILIAM GROUP LLC	 
	 	 
	By:	/s/ Alan G. Mnuchin	 
	 	Name: Alan G. Mnuchin	 
	 	Title:	 

 

 

 

[Signature Page to Administrative Services
Agreement]EX-10.1

 Exhibit 10.1 

Certain information contained in this document, identified by [***], has been redacted because it is both (i) not material and (ii) would likely cause
competitive harm to the Registrant if publicly disclosed. 
  
  

 
 AND 

OPTHEA 
 Commercial
License Agreement 
 Date: October 28, 2013 

  
 Selexis 2013 

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

 This Commercial License Agreement (this “Agreement”) is made effective on October 28,
2013 (the “Effective Date”) 
 by and between 

Selexis SA, a company incorporated under the laws of Switzerland, with its registered office at [***], Geneva, Switzerland
(“SELEXIS”) 
 and 

OPTHEA PTY LTD, a company incorporated under the laws of Australia, with its registered office at Level 4, 650 Chapel Street, South Yarra,
Victoria 3141, Australia (“COMPANY”) 
 (SELEXIS and COMPANY, collectively the “PARTIES” and, individually, a
“PARTY”) 
 Preamble 
  

	A.	 WHEREAS, COMPANY is a biopharmaceutical company engaged in the research, development,
manufacturing and sale of biopharmaceutical products; 

  

	B.	 WHEREAS, SELEXIS is a biotechnology company engaged in the development and sale of recombinant
cell lines based on the SELEXIS Technology; 

  

	C.	 WHEREAS, SELEXIS is the owner of certain Confidential Information, the SELEXIS Know-How and the SELEXIS Patent Rights; 

  

	D.	 WHEREAS, pursuant to a services agreement between the PARTIES dated November 26, 2012 (the
“Services Agreement”) SELEXIS has developed certain recombinant cell line(s) for COMPANY using the SELEXIS Technology and COMPANY has evaluated such cell Line(s); and 

 

	E.	 WHEREAS, SELEXIS is willing to grant COMPANY, and COMPANY is willing to receive from SELEXIS, a
license to the SELEXIS Know-How and the SELEXIS Patent Rights with respect to the recombinant cell lines, on the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, the PARTIES agree as follows: 

  

					
	Date: October 28, 2013	 	2 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.	 Definitions 

In addition to the terms defined above, the following terms, whether used in the singular or plural, shall have the following meanings as used in this
Agreement, unless otherwise specifically indicated: 
  

	1.1.	 “Affiliate” shall mean any Person that, as of the Effective Date, directly or
indirectly, controls, is controlled by, or is under common control with the relevant Person. For the purposes of this definition only, “control” shall mean the possession, directly or indirectly, of the power to cause the
direction of the management and policies of a Person, whether through ownership of voting securities of such Person, by contract or otherwise. A Person shall only be considered an Affiliate for so long as such Control exists. 

 

	1.2.	 “BLA” shall mean a Biologic License Application for the Final Product filed with the
FDA or any comparable filing made with a Regulatory Authority in another country. 

  

	1.3.	 “Calendar Quarter” shall mean, for each Calendar Year, each of the three month periods
ending March 31, June 30, September 30 and December 31 respectively. 

  

	1.4.	 “Calendar Year” shall mean the period commencing on January 1 and ending twelve
(12) consecutive calendar months later on December 31. 

  

	1.5.	 “Cell Line” shall mean a mammalian cell line that is developed using the SELEXIS
Technology. Cell Line shall include, without limitation, any COMPANY Cell Line(s). 

  

	1.6.	 “Clinical Trials” shall mean human studies designed to measure the safety and/or
efficacy of the Product. Clinical Studies include Phase I Clinical Trials, Phase II Clinical Trials, and Phase III Clinical Trials. 

  

	1.7.	 “Collaboration Partner” shall mean a Third Party with which COMPANY collaborates on the
development of the production process and/or commercialization of a Licensed Product or Final Product or to which COMPANY has granted a license for the development of the production process and/or commercialization of a Product.

  

	1.8.	 “Combination Product Adjustment” shall mean the adjustment of: Net Sales for any
combination product done by multiplying actual Net Sales of such combination product by the fraction A/(A + B) where [***], if sold separately, and [***], if sold separately. If, on a
country-by-country basis, the other active ingredient, device or component in the combination is not sold separately, Net Sales shall be calculated by multiplying actual
Net Sales of the combination product in such country by the fraction A/C where [***], if sold separately, in such country and [***]. 

  

	1.9.	 “Commercial License” shall have the meaning set out in Article 2.1.

  

	1.10.	 “Commercial License Option” shall mean the option granted to Company in the Services
Agreement to obtain a non-exclusive commercial license. 

  

					
	Date: October 28, 2013	 	3 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.11.	 “COMPANY Technology” shall mean any Technology owned or controlled by COMPANY,
including, without limitation, any such Technology related to Licensed or Final Product, but excluding any SELEXIS Technology related thereto. 

  

	1.12.	 “COMPANY Cell Line” shall mean the mammalian cell line developed by SELEXIS and
provided to COMPANY pursuant to the Services Agreement and any progeny or derivatives thereof. A Cell Line which has been [***] shall be described as such in this Agreement. 

 

	1.13.	 “Confidential Information” shall mean any technical and business information pertaining
to materials and production techniques, products, processes and services, including without limitation physical working models and samples of the products, research, development, patentable and unpatentable inventions, manufacturing, purchasing and
product development plans, forecasts, strategies and information, engineering, marketing, merchandising, selling, customer lists, customer prospects, software codes, algorithms, names and expertise of employees and consultants, blueprints, technical
information, trade secrets or know-how or other related proprietary business information and data, in any case whether such information is provided in tangible or intangible form, written, oral, graphic,
pictorial or recorded form or stored on computer discs, hard drives, magnetic tape or digital or any other electronic medium. Confidential Information disclosed in any tangible format will be labeled “Confidential” or words to similar
effect, and all non-tangible disclosures will be declared to be “Confidential” or words to similar effect at the time of disclosure. Confidential Information shall include any and all material and
data created by the receiving party based on, containing or otherwise reflecting Confidential Information. Confidential Information shall also include any such information or documents which may be disclosed hereunder which the disclosing party
received in confidence from a Third Party. 

  

	1.14.	 “Contract Manufacturing Organization” shall mean an entity of which at least fifty
percent (50%) of the business is directed toward the provision of services or products for non-affiliate third parties. 

 

	1.15.	 “Contractor” shall mean a Third Party contractor who: (i) develops the production
process for Licensed Products or Final Products by or on behalf of COMPANY or (ii) manufactures and supplies Licensed Products or Final Products by using such production process by or on behalf of Company. 

 

	1.16.	 “Default” shall have the meaning set out in Article 9.2. 

 

	1.17.	 “Defaulting Party” shall have the meaning set out in Article 9.2.

  

	1.18.	 “Deliverables” shall mean the reports and other data delivered to COMPANY
pursuant to the Services Agreement, excluding the COMPANY Cell Line. 

  

					
	Date: October 28, 2013	 	4 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.19.	 “FDA” shall mean the United States Food and Drug Administration, or any successor
agency. 

  

	1.20.	 “Final Product” shall mean any pharmaceutical preparation in final form
containing any Licensed Products for sale by prescription, over-the-counter or any other method, in any dosage form, formulation, presentation, line extension or package
configurations, including without limitation such Product in development where the context so requires in this Agreement. 

  

	1.21.	 “First Commercial Sale” shall mean, with respect to any Final Product in any country,
the first sale of such Final Product for use or consumption by the general public in such country after Regulatory Approval as well as Pricing and Reimbursement Approval for such Final Product has been obtained in such country. For the avoidance of
doubt, sales prior to receipt of all Regulatory Approvals and Pricing and Reimbursement Approvals necessary to commence regular commercial sales, such as so-called “treatment IND sales”, “named
patient sales” and “compassionate use sales”, shall not be construed as a First Commercial Sale. 

  

	1.22.	 “Force Majeure” shall mean conditions beyond the control of a PARTY, including without
limitation, an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of facilities or materials by fire,
earthquake, storm or the like catastrophe, and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence and prudence that would be reasonably and ordinarily expected from a skilled
and experienced person engaged in the same type of undertaking under the same or similar circumstances). 

  

	1.23.	 “IND” shall mean an Investigational New Drug Application for the Product filed with the
FDA or any comparable filing made with a Regulatory Authority in another country. 

  

	1.24.	 “Insolvent Party” shall have the meaning set out in Article 9.3. 

 

	1.25.	 “Invention” shall mean any invention, idea, innovation, enhancement, improvement or
feature, whether or not patentable or registrable, together with any intellectual property rights relating thereto (including without limitation the Patent Rights and rights to confidentiality and proprietary information). 

 

	1.26.	 “Know-How” shall mean information in whatever
form, tangible or intangible and on whatever medium, including without limitation, information and materials relating to Inventions and other know-how, trade secrets, data (including without limitation all
data from pre-clinical and clinical studies and other studies intended for regulatory submission), results, formulae, DNA and amino acid sequence information and developments. 

 

	1.27.	 “Licensed Field of Use” shall mean all uses of a Licensed and/or Final Product.

  

	1.28.	 “Licensed Product” shall mean the recombinant protein listed in Exhibit 2.

  

					
	Date: October 28, 2013	 	5 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.29.	 “Losses” shall mean all and any liability, damage, loss or expense.

  

	1.30.	 “Net Sales” shall mean the amount collected by COMPANY, its Affiliates and/or its
sublicensees on account of sales of Final Product to Third Parties in the Territory, less the following deductions: 

  

	 	(i)	 [***]; 

  

	 	(ii)	 [***]; 

  

	 	(iii)	 [***]; 

  

	 	(iv)	 [***]; 

  

	 	(v)	 [***]; and 

  

	 	(vi)	 in the event that a Final Product is sold in any country in the form of a combination product containing one or
more other therapeutically active ingredients, the Net Sales for any such Final Product shall be computed using the Combination Product Adjustment for such country. 

 

	1.31.	 “Non-Defaulting Party” shall have the meaning
set out in Article 9.2. 

  

	1.32.	 “Notice of Default” shall have the meaning set out in Article 9.2.

  

	1.33.	 “Patent Rights” shall mean any and all of the following: (i) patent applications
(including without limitation provisional patent applications) and patents (including without limitation the inventor’s certificates); (ii) any substitution, extension (including without limitation patent term extensions and supplementary
protection certificates), registration, confirmation, reissue, continuation, divisional, continuation-in-part, re-examination,
renewal, patent of addition or the like thereof or thereto; (iii) any foreign counterparts of any of the foregoing; and (iv) any utility model applications and utility models (whether or not corresponding to any of the foregoing).

  

	1.34.	 “Person” shall mean an individual, a partnership, a joint venture, a corporation, a
limited liability company, a trust, an estate, an unincorporated organization, or any other entity, or a government or any department or agency thereof, whether acting in an individual, fiduciary or other capacity. 

 

	1.35.	 “Phase I Clinical Trial” shall mean a Clinical Trial conducted in humans which is
principally intended to obtain data on the safety, tolerability, pharmacokinetic or pharmacodynamic properties of a product. Phase I shall be deemed to have commenced when the first patient in the study has been treated. Phase I shall be deemed to
have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the
primary endpoint. 

  

					
	Date: October 28, 2013	 	6 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.36.	 “Phase II Clinical
Trial” shall mean a Clinical Trial conducted in humans in which the primary objective is a preliminary determination of therapeutic efficiency and/or to find an optimal dose range in patients with the disease target being
studied. Phase II shall be deemed to have commenced when the first patient in the study has been treated. Phase II shall be deemed to have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial
as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the primary endpoint. 

  

	1.37.	 “Phase III Clinical Trial” shall mean a Clinical Trial conducted in humans in which the
primary objective is a determination of therapeutic efficiency in patients with the disease target being studied. Phase III shall be deemed to have commenced when the first patient in the study has been treated. Phase III shall be deemed to have
completed when the last patient has completed his or her treatment being investigated by that Clinical Trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the primary
endpoint. 

  

	1.38.	 “Price and Reimbursement Approval” shall mean any approvals, licenses, registrations or
authorizations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary to determine or set the pricing of a Product, and/or its reimbursement
level by the relevant health authorities, providers or other funding institutions, at supranational, national, regional, state or local level. 

  

	1.39.	 “Regulatory Approval” shall mean any approvals, licenses, registrations or
authorizations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary for the manufacture, marketing or sale of a Product or conduct of Clinical
Trials in a regulatory jurisdiction, excluding Price and Reimbursement Approval. 

  

	1.40.	 “Regulatory Authority” shall mean (i) the FDA or (ii) any and all
governmental or supranational agencies, ministries, authorities or other bodies with similar regulatory authority with respect to approval or registration of pharmaceutical or biologic products in any other jurisdiction anywhere in the world.

  

	1.41.	 “Royalty Term” shall mean with respect to each Final Product sold in a particular
country, the period beginning on the date of the First Commercial Sale in such country and terminating on the expiration of the last-to-expire or lapse of any Valid Claims in such country covering the Licensed Product, the Final Product, the Company
Cell Line, or any other Cell Line used to produce Licensed Product, or the development, use, or manufacture of any of the foregoing. In no event shall the Royalty Term exceed the 22nd of October
2024. 

  

	1.42.	 “SELEXIS Know-How” shall mean SELEXIS’
Confidential Information and Know-How owned, controlled by SELEXIS, or to which SELEXIS has received a license which includes a right to grant sublicenses consistent with the Commercial License relating to,
without limitation, the construction and development of recombinant cell lines for the manufacture of biopharmaceutical products and existing as of the Effective Date or obtained thereafter during the Term. 

 

	1.43.	 “SELEXIS Materials” shall mean the materials provided by SELEXIS to COMPANY under this
Agreement and all modifications and improvements thereof made by SELEXIS during the Term, if any. SELEXIS Materials excludes the Cell Lines. 

  

					
	Date: October 28, 2013	 	7 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.44.	 “SELEXIS Patent Rights” shall mean Patent Rights which: (i) are owned or
controlled by SELEXIS, or to which SELEXIS has received a license which includes a right to grant sublicenses consistent with the Commercial License (ii) are necessary or useful for the use of SELEXIS Materials or the construction, development
and use of Cell Lines and (iii) are existing as of the Effective Date or obtained thereafter during the Term. Without limiting the generality this Article, the SELEXIS Patent Rights as of the Effective Date are listed in Exhibit 1 hereto.

  

	1.45.	 “SELEXIS Technology” shall mean the SELEXIS Patent Rights, the SELEXIS Know-How and the SELEXIS Materials. 

  

	1.46.	 “Tax Authority” shall mean the relevant governing tax authority as defined in Article
4.2. 

  

	1.47.	 “Taxes” shall mean all excises, taxes and duties with the exception of VAT.

  

	1.48.	 “Technology” shall mean all inventions (whether or not patentable or patented) and
intellectual property rights therein, including without limitation, patents, patent applications, know-how, trade secrets, copyrights, trademarks, designs, concepts, registered and unregistered design rights,
data, work product, results, reports, improvements, business and research plans, analytic methods and results, experimental methods and results, manufacturing processes, developments, technologies, technical information, composites of genes and gene
constructs, cell lines, manuals, standard operating procedures, instructions and specifications. 

  

	1.49.	 “Term” shall have the meaning set out in Article 9.1. 

 

	1.50.	 “Territory” shall mean the entire world. 

 

	1.51.	 “Third Party” shall mean a Person other than SELEXIS, COMPANY or an Affiliate of
SELEXIS or COMPANY. 

  

	1.52.	 “Transferee” shall have the meaning set out in Article 2.3. 

 

	1.53.	 “Valid Claim” shall mean any issued or granted claim of the SELEXIS Patent Rights that
has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, that is unappealable or remains unappealed at the end of the time allowed for appeal, or that has not been
disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 

 

	1.54.	 “VAT” shall mean value added tax and any other similar turnover, sales or purchase, tax
or duty levied by any other jurisdiction whether central, regional or local. 

  

					
	Date: October 28, 2013	 	8 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	2.	 Commercial Licenses 

 

	2.1.	 Commercial Licenses. Subject to COMPANY’s compliance with the other terms and conditions of this
Agreement (including, without limitation, payment by COMPANY of the amounts provided for below in accordance with the payment schedule and terms provided for below), SELEXIS hereby grants to COMPANY a
non-exclusive worldwide license under the SELEXIS Patent Rights and SELEXIS Know-How, in the Territory, with the limited right to sublicense in accordance with Article
2.2, to use Cell Lines, Deliverables and SELEXIS Materials for the manufacture of Licensed and/or Final Products, and to make, have made, use, offer for sale, sell, import and otherwise exploit Licensed and/or Final Products in the Licensed Field of
Use, including, without limitation, the use of Licensed and/or Final Products in Clinical Trials (the “Commercial License”). 

  

	2.2.	 Sublicenses. Subject to the provisions of this Article 2.2, COMPANY shall be entitled to grant
sublicenses to the rights granted under the Commercial License to any one or more third parties (the “Sublicensees”) provided always: 

  

	 	2.2.1.	 Any sublicense granted under this Agreement shall be expressly subject and subordinate to the terms of this
Agreement and it shall be COMPANY’s responsibility to ensure strict adherence by any Sublicensee to the terms and conditions of this Agreement. 

  

	 	2.2.2.	 Any Sublicensee shall not, by virtue of this Agreement, be granted any right or licence, either express or
implied, under any SELEXIS Know-how and/or SELEXIS Patent Rights to use COMPANY Cell Lines, SELEXIS Materials and/or SELEXIS Patent Rights other than for the purposes of the manufacture, use, offer for sale,
sale, import and other exploitation of Licensed and/or Final Products in the Field. 

  

	 	2.2.3.	 COMPANY will notify SELEXIS in writing of any such sublicense within [***] following the grant thereof, and
[***]. 

  

	 	2.2.4.	 Notwithstanding the above, COMPANY is and remains fully liable and responsible for any breach of this Agreement
committed or any Losses caused by any Sublicensee, or any other Third Party or Affiliate to whom the Cell Lines, Deliverables, SELEXIS Materials and the SELEXIS Know-How or parts thereof are made available
under any such sublicense. 

  

	2.3.	 Transfer of SELEXIS Materials. COMPANY shall not transfer the Cell Lines, Deliverables, SELEXIS
Materials or SELEXIS Know-How to any Third Party, except that during and for the Term only, COMPANY may transfer Cell Lines, Deliverables, SELEXIS Materials and SELEXIS
Know-How to Contractors or 

  

					
	Date: October 28, 2013	 	9 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	
Collaboration Partners (the “Transferees”) solely for their use in connection with the development of a production process for Licensed and/or Final Product, the manufacturing of
Licensed and/or Final Product for sale or distribution of Final Product in the Licensed Field of Use, or, the commercialization of Licensed and/or Final Product in the Licensed Field of Use, with, for or on behalf of, COMPANY. If COMPANY makes any
such transfer, it shall notify SELEXIS within [***] of any such transfer and report the name and address of any Transferee together with confirmation that the Transferee has agreed in writing to adhere to the confidentiality obligations and use
restrictions set out in this Agreement. 

 For the avoidance of doubt, upon expiration of the last Royalty Term, the Commercial
License granted to COMPANY in Article 2.1 (and the sublicense and transfer rights as set forth in Articles 2.2 and 2.3) shall become perpetual and royalty-free. 
  

	2.4.	 Sale of Licensed Product. If COMPANY (itself or in cooperation with one or more Third Parties) wishes to
sell or otherwise transfer Licensed Product to any Third Party in a form other than as a Final Product, it may do so subject to the following. (a) Such Licensed Product may only be sold or transferred to one or more Third Party(ies) for use in
Clinical Trials, for further research and/or development and/or for formulation for ultimate sale in the Licensed Field of Use as Final Product; (b) Any sale for financial consideration of Licensed Product in a form other than as a Final
Product will be deemed a “Net Sale” of Final Product and Royalty Payments will be due on such sale of Licensed Product in accordance with Article 3.1.3 as if the Licensed Product were Final Product; and (c) All sales of Final Product
incorporating such Licensed Product will be deemed “Net Sales” of a Sublicensee for purposes of this Agreement and will be subject to payment by COMPANY of the royalties set forth in Article 3.1.3, and will trigger payment of the
milestones set forth in Article 3.1.2 if a Final Product produced by such a Third Party is the first Final Product to reach the appropriate milestone trigger point. COMPANY will ensure that sufficient records are kept by COMPANY or available to it
to document the Net Sales of Licensed and/or Final Products to determine the amounts due to SELEXIS under Article 3. 

  

	3.	 Consideration 

 

	3.1.	 Payments. In consideration of the Commercial License granted to COMPANY pursuant to Article 2.1, and in
consideration of the right to sublicense the rights granted in Article 2.1 pursuant to Article 2.2, COMPANY shall pay SELEXIS as follows: 

  

	 	3.1.1.	 Commercial License Execution Payment. COMPANY shall pay SELEXIS a
one-time fee of thirty five thousand Swiss Francs (CHF 35,000), due upon execution of this Agreement. 

  

					
	Date: October 28, 2013	 	10 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	3.1.2.	 Commercial License Milestone Payments. COMPANY shall make the following milestone payments to SELEXIS
with respect to the first occurrence of each such milestone event for each Licensed Product: 

  

	 	3.1.2.1    [***];	 

  

	 	3.1.2.2    [***];	 

  

	 	3.1.2.3    [***];  and	 

  

	 	3.1.2.4    [***].	 

  

	 	3.1.3.	 Commercial License Royalty Payments: In addition to the milestone payments under Article 3.1.2, during
the Royalty Term COMPANY shall pay SELEXIS on a Final Product-by-Final Product (including Products deemed Final Products in accordance with Article 2.4, parts
(b) and (c)) and country-by-country basis a royalty of [***] of Net Sales of all Final Products sold worldwide, where said Final Products have been produced from a
Cell Line [***]. If Final Products have been produced from a Cell Line [***], then the royalty rate shall be [***]. Where royalties are due for the sale of Final Products directly by COMPANY such royalties shall be paid for each Calendar Quarter
within [***] of the end of that Calendar Quarter. Where royalties are due for the sales of Final Product by a Sublicensee, payment shall be made within [***] of the end of that Calendar Quarter. For the avoidance of doubt, no royalty payments shall
be due for a Final Product in a specific country after the Royalty Term has expired for such Final Product in such country. Where royalties are no longer due in accordance with the foregoing, the Commercial License granted to COMPANY under this
Agreement shall become perpetual, irrevocable, fully paid up and royalty free with respect to such Licensed and Final Product in such country. At any time during the Term, SELEXIS and COMPANY may agree to remove the royalty in its entirety or in
part in exchange for payment(s) as negotiated. 

  

	3.2.	 Mechanism of Payment. The payments due to SELEXIS under this Agreement shall be made by wire transfer or
electronic fund transfer to the credit and account of SELEXIS as follows: 

 Bank Name :    [***] 

Account:           [***] 

To:                    Selexis S.A. 

                       
   [***] 
  

	3.3.	 Payment Terms. Except with respect to royalties due pursuant to Article 3.1.3, COMPANY shall make
payments due to SELEXIS under this Agreement at the latest [***] after receipt of invoice. All fees and payments, including without limitation under Article 3.1.3, do not include any applicable VAT or Taxes. 

  

					
	Date: October 28, 2013	 	11 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	3.4.	 Records. COMPANY and its Affiliates and Sublicensees shall keep true accounts of Net Sales of Final
Products and COMPANY shall deliver to SELEXIS at the same time as the payments due under Article 3.1.3. a written account, including quantities of Net Sales of each such Final Product, broken down on a country-by-country basis with respect to those payments. SELEXIS is entitled to have such accounts audited by an independent expert of its choice. Such independent expert shall be bound by confidentiality
terms at least as restrictive as the terms of Article 8 and shall be authorized to disclose to SELEXIS only the results of its audit. COMPANY shall provide access to all information reasonably requested by such expert. The cost of any audit shall be
borne by SELEXIS unless the audit shows that COMPANY underpaid SELEXIS by [***] of the amounts due in which case the cost of the audit shall be borne by COMPANY. 

 

	3.5.	 Single Royalty and Milestone. For Final Products covered by more than one SELEXIS Patent Rights, COMPANY
will make one payment to SELEXIS for royalties on any unit of Final Product sold by COMPANY or Sublicensees, irrespective of how many SELEXIS Patent Rights may cover such Final Product. Each milestone described in Article 3 shall be payable only
once in relation to each Licensed Product, irrespective of the number of Final Products which incorporate that Licensed Product and undergo the events triggering the payment. All fees and payments, including without limitation under Article 3.1, do
not include any applicable VAT or Taxes. 

  

	4.	 Taxes 

  

	4.1.	 General. All Taxes levied on account of any payment made by COMPANY to SELEXIS pursuant to this
Agreement (other than Taxes on income, gains or profits levied against SELEXIS by any competent Swiss tax authority) will be the responsibility of, and shall be paid by, COMPANY pursuant to Article 3. 

 

	4.2.	 Character of Payments. The PARTIES agree that, for purposes of determining the applicability of any
Taxes, the payments to be made under this Agreement constitute payments for tangible property and license of intellectual property. However, in the event that the governing tax authority (the “Tax Authority”) qualifies differently
such payment, any additional taxes that may be applied (including without limitation any interest and penalties that may be unpaid) shall be paid by COMPANY. 

 

	4.3.	 Withholding by COMPANY. 

 

	 	4.3.1.	 All payments by COMPANY hereunder shall be made in full without any deduction or withholding whatsoever and
free and clear of and without any deduction or withholding for or on account of any Taxes, except to the extent that any such deduction or withholding is required by law in effect at the time of payment. If any such deductions or withholdings must
be made from any amounts payable or paid by COMPANY, COMPANY shall [***]. 

  

					
	Date: October 28, 2013	 	12 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	4.3.2.	 Each PARTY shall execute and deliver such documents, deeds and other papers and take such further actions as
may be reasonably required to lawfully enable SELEXIS and COMPANY or their respective Affiliates or Sublicensees to mitigate withholding taxes, such as take advantage of any applicable legal provision or any double taxation treaties, for the purpose
of assigning to SELEXIS full tax credit for amounts deducted or withheld by COMPANY pursuant to Article 4.3.1. 

  

	5.	 Intellectual Property 

 

	5.1.	 Ownership. Each PARTY shall retain all right, title and interest in and to its Inventions and Know-How which exist on the Effective Date or which are thereafter developed independently of the performance of this Agreement. 

 

	5.2.	 COMPANY and SELEXIS Inventions. Any Invention developed hereunder by or for either Party, solely or
jointly with the other PARTY or any Affiliate or agent thereof, shall belong exclusively (i) to COMPANY, to the extent [***] (“COMPANY Invention”); or (ii) to SELEXIS, to the extent [***] (“SELEXIS
Invention”). Any SELEXIS Inventions shall be included within the scope of the SELEXIS Technology licensed to COMPANY under this Agreement as provided for in Article 5.5. Notwithstanding the foregoing, such ownership shall not be construed
to transfer to either PARTY ownership of or any license or other rights in or to any of such PARTY’s underlying Technology which may be included or embodied therein, or useful or necessary to use in connection with exploiting such Invention.

  

	5.3.	 Other Inventions. Except as set forth in Article 5.2, any other Invention developed hereunder solely by
COMPANY shall be COMPANY’s sole property and any other Invention developed hereunder solely by SELEXIS shall be SELEXIS’ sole property. The PARTIES do not anticipate that there will be any jointly developed Inventions hereunder, but if
there are any other such jointly developed Inventions which do not relate to either the SELEXIS Technology or the COMPANY Technology, such Inventions shall be owned jointly by COMPANY and SELEXIS (“Joint Inventions”). In the event
any such Joint Inventions arise, the PARTIES will use commercially reasonable efforts to cooperate to protect and/or exploit such Joint Inventions, including, without limitation, by sharing in costs incurred with protection of such Joint Inventions
and sharing in revenues generated by the use or sublicense of the Joint Inventions. 

  

	5.4.	 Notification. Each PARTY shall promptly notify the other PARTY of any Invention arising in connection
with this Agreement provided that COMPANY has no obligation to notify SELEXIS with respect to any COMPANY Inventions developed solely by COMPANY. 

  

					
	Date: October 28, 2013	 	13 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	5.5.	 Improvements. In the event SELEXIS possesses, acquires, creates or is licensed (with the right to grant
a sublicense consistent with the terms of the Commercial License) any improvements to the SELEXIS Technology which are necessary or useful for COMPANY to use in connection with the use of the Cell Lines as licensed hereunder, such improvements shall
automatically be included in the SELEXIS Patent Rights and/or the SELEXIS Know-How and thereby disclosed and licensed at no extra cost to COMPANY in accordance with this Agreement; provided, however, that any
rights granted by the foregoing will be subject to COMPANY’s compliance with any bona fide obligations owed to Third Parties (with respect to which SELEXIS has notified COMPANY), including, without limitation, and royalty obligations owed to
Third Parties. 

  

	5.6.	 Third Party Patent Rights. SELEXIS covenants that if SELEXIS becomes aware that COMPANY’s use of
the SELEXIS Technology in accordance with the terms hereunder would or would likely infringe any Third Party proprietary rights, SELEXIS shall use its reasonable commercial efforts to resolve such potential infringement at SELEXIS’ cost to
ensure COMPANY’s freedom to continue to exercise the licenses granted under this Agreement, including without limitation by using its reasonable commercial efforts to obtain a license from the Third Party owner of the proprietary rights which
entitles SELEXIS to continue to grant the rights to COMPANY as provided for herein. Should such efforts not be successful, SELEXIS shall inform COMPANY in writing and thereafter the Parties will discuss the matter in good faith for a period not to
exceed [***]. Thereafter [***], save that SELEXIS shall not have such right if COMPANY agrees to [***]. If COMPANY [***] and if COMPANY [***] relating to COMPANY’s permitted use of the SELEXIS Technology hereunder, then COMPANY may deduct any
royalties actually paid to such Third Party to the extent related to the use of the SELEXIS Technology [***]; provided that in no event shall the [***] of the royalty amount that would have otherwise been payable for such Final Product. The
obligations set forth in this Article relate solely to Third Party rights related specifically and solely to the SELEXIS Technology licensed hereunder, and do not apply with respect to any other technology or materials used by COMPANY at its
discretion in connection with its exercise of the license rights granted hereunder, and specifically exclude any such Third Party rights to the extent relating to the Licensed Product(s) produced by any Cell Lines hereunder. 

 

	5.7.	 Enforcement of SELEXIS Patent Rights. If, during the Term, either PARTY becomes aware of any
infringement or potential infringement of the SELEXIS Technology it shall promptly notify the other PARTY in writing and the PARTIES shall consult with each other to decide the best way to respond to such infringement or misuse, provided that
SELEXIS shall remain free to take any action as it deems fit in its sole discretion. 

  

	5.8.	 COMPANY Publications. COMPANY shall have the unrestricted right to publish or otherwise disclose the
results and data obtained by the practice of the SELEXIS Technology in accordance with the terms hereof, provided such publication or disclosure does not include any Confidential Information of SELEXIS. The name of SELEXIS shall be given proper
recognition in such publication(s) as scientifically appropriate. 

  

					
	Date: October 28, 2013	 	14 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	5.9.	 Further Assurance. Each PARTY agrees to execute and do all things at the cost of the other PARTY (if not
specifically agreed otherwise) as the other PARTY may reasonably require to give that other PARTY the full benefit of the provisions of this Article 5. 

  

	6.	 Representations, Warranties, and Covenants 

 

	6.1.	 General. Except for the representations, warranties and covenants contained in Article 5.6 or this
Article 6, the PARTIES do not make any other representations, nor give any other warranties, express or implied, nor undertake to any other covenants. The PARTIES expressly exclude any and all other representations, warranties and covenants.

  

	6.2.	 Representations and Warranties by the PARTIES. Each PARTY hereby represents and warrants to the other
PARTY that: 

  

	 	6.2.1.	 Corporate Power. It is duly organized and validly existing under the laws of the state (or country or
other jurisdiction, as the case may be) of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 

 

	 	6.2.2.	 Due Authorization. It is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder and the persons executing this Agreement on its behalf have been duly authorized to do so by all requisite corporate actions. 

  

	 	6.2.3.	 Binding Agreement. This Agreement is a legal and valid obligation binding upon it and is enforceable in
accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable
principles and public policy. 

  

	 	6.2.4.	 No Conflicts. The execution, delivery and performance of this Agreement by it does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a PARTY or by which it may be bound. 

  

	 	6.2.5.	 Intellectual Property Rights. Each PARTY represents that it has valid and sufficient arrangements and
agreements with its directors, officers and employees (which term shall include agents, consultants and subcontractors) such that ownership of intellectual property rights in and to any Inventions made by its directors, officers and employees vests
in such PARTY. 

  

					
	Date: October 28, 2013	 	15 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	6.3.	 Additional Representations and Warranties by SELEXIS. SELEXIS hereby represents and warrants that, to
the best of its knowledge, as of the Effective Date: 

  

	 	6.3.1.	 There is no pending litigation asserting that the use of the SELEXIS Technology or the SELEXIS Know-How constitutes an infringement or misappropriation of any intellectual property rights of a Third Party; and 

  

	 	6.3.2.	 SELEXIS has the right in and to the SELEXIS Technology, SELEXIS
Know-How and the SELEXIS Patents to grant COMPANY the rights which are granted to COMPANY under this Agreement. 

  

	6.4.	 Additional Warranties by COMPANY. COMPANY hereby represents and warrants to SELEXIS that:

  

	 	6.4.1.	 To the best of its knowledge, there are no Third Party intellectual property rights or any other rights that
may be asserted against SELEXIS claiming that SELEXIS was or is directly infringing or is helping or assisting COMPANY in infringing such Third Party’s rights in connection with COMPANY’s exercise of the Commercial License granted by
SELEXIS hereunder (except to the extent that any such Third Party rights relate solely and specifically to the SELEXIS Technology and/or SELEXIS Materials), including, without limitation, the development, manufacture and commercialization of
Licensed Products and/or Final Products as permitted hereunder; and 

  

	 	6.4.2.	 As of the Effective Date, to the best of its knowledge, there is no litigation pending against COMPANY in
connection with the use or ownership of the Licensed Product, including, without limitation, the infringement or misappropriation of any intellectual property rights of a Third Party relating to the Licensed Product, and COMPANY has not received any
written claim that the use thereof infringes on any intellectual property rights of a Third Party or a request or demand from any Third Party for the licensing of any intellectual property rights to such Third Party in connection with the use of the
Licensed Product. 

  

	 	6.4.3.	 COMPANY will use commercially reasonable endeavours to not knowingly misappropriate or infringe the
intellectual property or other rights of any Third Party in connection with its exercise of its licensed rights hereunder, including, without limitation, use of any SELEXIS Technology, Cell Line, or Deliverables, or development, manufacture or sale
of Licensed and/or Final Product hereunder. 

  

	6.5.	 Third Party Intellectual Property. Without limiting the warranty set forth in Article 6.4.3, COMPANY
hereby acknowledges that in order to make, have made, use, offer for sale, sell, import and otherwise exploit Licensed and/or Final Products in the Field it may require licenses under Third Party patent or other intellectual property rights that may
be infringed by the manufacture, use, offer for sale, sale, importation and other exploitation of Licensed and/or Final Product and, other than in the case of Third Party patent rights provided for in Article 5.6, it is agreed that it shall be
COMPANY’S responsibility to identify all such intellectual property and satisfy itself as to the need for such licences, and, if necessary, to obtain such licenses. COMPANY agrees that, with the sole exception of Third Party patent rights
provided for in Article 5.6 and for which SELEXIS provides indemnification in Article 7.1, SELEXIS will have no liability whatsoever for any infringement of Third Party patent rights. 

  

					
	Date: October 28, 2013	 	16 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	6.6.	 Disclaimer of Warranties by SELEXIS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT AND WITHOUT
LIMITING THE GENERALITY OF ARTICLE 6.1, SELEXIS DOES NOT MAKE NOR GIVE ANY REPRESENTATION OR WARRANTY TO COMPANY OF ANY NATURE, EXPRESS OR IMPLIED, THAT THE SELEXIS TECHNOLOGY WILL BE USEFUL FOR, OR ACHIEVE ANY PARTICULAR RESULTS AS A RESULT OF ANY
USE THEREOF BY SELEXIS OR BY COMPANY PURSUANT TO ANY LICENSE GRANTED TO COMPANY UNDER THIS AGREEMENT. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, SELEXIS SPECIFICALLY DISCLAIMS ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE. 

  

	7.	 Liability and Indemnification 

 

	7.1.	 Indemnification by SELEXIS. During the Term of this Agreement and thereafter, SELEXIS hereby agrees to
save, defend and hold COMPANY, its Affiliates, and their respective officers, directors, employees, consultants and agents harmless from and against any and all Losses resulting directly from (i) any Third Party claim alleging that [***]; or
(ii) any material breach of SELEXIS’ representations, warranties and covenants set forth in Article 6; except in each case to the extent that such Losses were caused by willful misconduct or gross negligence of COMPANY or any of its
Affiliates, Collaborators or Sublicensees. In the event COMPANY seeks indemnification under this Article 7.1, COMPANY shall notify SELEXIS of any claim as soon as reasonably practicable after it receives notice of the claim. COMPANY shall allow
SELEXIS to conduct and control the defense against the claim (including without limitation to settle the claim solely for monetary consideration), shall (at SELEXIS’ expense) execute and deliver such documents and other papers and take such
further actions as may be reasonably required to defend against the claim (including without limitation to settle the claim solely for monetary consideration) and shall (at SELEXIS’ expense) cooperate as requested by SELEXIS in the defense of
the claim, provided always that SELEXIS may not settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding which includes any admission as to liability or fault without the prior express
written consent of COMPANY, which consent will not be unreasonably withheld. 

  

	7.2.	 Indemnification by COMPANY. During the Term of this Agreement and thereafter, COMPANY hereby agrees to
save, defend and hold SELEXIS and its officers, directors, employees, consultants and agents harmless from and against any and all Losses resulting from (i) Third Party claims in connection with [***]; (ii) Third Party claims relating to [***];
or (iii) any material breach of COMPANY’s representations, warranties 

  

					
	Date: October 28, 2013	 	17 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	
and covenants set forth in Article 6; in each case, except to the extent that such Losses result from the willful misconduct or gross negligence of SELEXIS. In the event SELEXIS seeks
indemnification under this Article, SELEXIS shall notify COMPANY of any claim as soon as reasonably practicable after it receives notice of the claim. SELEXIS shall allow COMPANY to assume direction and control of the defense of the claim (including
without limitation the right to settle the claim solely for monetary consideration), and shall (at COMPANY’s expense) execute and deliver such documents and other papers and take such further actions as may be reasonably required to defend
against the claim (including without limitation to settle the claim solely for monetary consideration). SELEXIS shall (at COMPANY’s expense) cooperate as requested by COMPANY in the defense of the claim, provided always that COMPANY may not
settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding which includes any admission as to liability or fault without the prior express written consent of SELEXIS, which consent will not
be unreasonably withheld. 

  

	7.3.	 No Incidental or Consequential Damages. In no event shall either PARTY be responsible for any incidental
or consequential damages, including without limitation, lost profits or opportunities; provided that the foregoing shall in no event limit a PARTY’s indemnification obligation under Article 7.1 or Article 7.2. 

 

	7.4.	 Limitation of Liability. SELEXIS’ cumulative liability under this Agreement, whether in contract,
in tort, or otherwise, shall in no event exceed the aggregate consideration paid by COMPANY to SELEXIS under this Agreement. 

  

	8.	 Confidentiality 

 

	8.1.	 Non-disclosure. During the Term of this Agreement and for [***]
thereafter, each PARTY shall keep Confidential Information of the other PARTY confidential and shall not (i) use the other PARTY’s Confidential Information for any purpose not expressly permitted under this Agreement, nor
(ii) disclose the other PARTY’s Confidential Information to any Person other than those of its agents, employees, and consultants (collectively, “Representatives”) who need to know such Confidential Information for a use or
purpose expressly permitted under this Agreement. Any such Representative who receives Confidential Information pursuant to this Article 8.1 shall be bound by written obligations of confidentiality and non-use
with respect to the Confidential Information that are no less stringent than the obligations set forth in this Agreement. 

  

	8.2.	 Exceptions. The confidentiality obligations set forth in Article 8.1 shall not apply to Confidential
Information that (i) is, or becomes, public information other than as the result of the violation of this Agreement or other 

  

					
	Date: October 28, 2013	 	18 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	
act or omission by the receiving PARTY or its Representatives; (ii) was lawfully known to the receiving PARTY or its Representatives without restriction on use or disclosure at the time of
disclosure hereunder; (iii) is hereafter lawfully received by the receiving PARTY or its Representatives from a Third Party authorized to make such disclosure and without restriction on use or disclosure; or (iv) is approved for release by
prior written consent from the disclosing Party. 

  

	8.3.	 Authorized Disclosures. Notwithstanding any provision of this Agreement to the contrary, each PARTY may
disclose Confidential Information of the other PARTY to the extent such disclosure is required by law, provided however that the receiving PARTY gives the disclosing PARTY reasonable prior written notice to enable the disclosing PARTY to take
appropriate measures to protect its Confidential Information and fully cooperates, subject to commercially reasonable efforts, with the disclosing PARTY to prevent or limit to the greatest extent possible the disclosure of Confidential Information.

  

	8.4.	 Use of Name. No right, express or implied, is granted to either PARTY by this Agreement to use in any
manner any trademark or trade name of the other PARTY including the names “CIRCADIAN, VEGENICS or OPTHEA” and “SELEXIS” without the prior written consent of the PARTY entitled to such trademark or trade name.

  

	9.	 Term and Termination 

 

	9.1.	 Term. This Agreement is effective as of the Effective Date. Unless earlier terminated pursuant to
Articles 9.2, 9.3 or 9.4 of this Agreement shall remain in full force and effect until [***] (the “Term”). 

  

	9.2.	 Termination for Default. In addition to any other remedies which may be available at law or equity, in
the event of any material breach of this Agreement (the “Default”) by a PARTY (the “Defaulting Party”), the PARTY not in default (the “Non-Defaulting Party”)
shall have the right to give the Defaulting Party a written notice thereof (the “Notice of Default”), which must state the nature of the Default in reasonable details and request that the Defaulting Party cure such Default within
[***]. During such [***] period, the Parties will cooperate in good faith in order to resolve any issue(s) that may have given rise to the Notice of Default and/or cure such Default. If such Default is not cured or the issue(s) that may have given
rise to the Notice of Default not resolved within [***] after receipt of a Notice of Default by the Defaulting Party or if such Default cannot be cured, the Non-Defaulting Party may, at its sole discretion,
terminate this Agreement by written notice effective upon receipt. For avoidance of doubt, if the Default is cured or the issue(s) that may have given rise to the Notice of Default resolved within [***] after receipt of a Notice of Default by the
Defaulting Party, the Non-Defaulting Party may not terminate this Agreement. 

  

					
	Date: October 28, 2013	 	19 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	9.3.	 Termination for Bankruptcy. In the event that a PARTY shall become insolvent or make any arrangement
with its creditors or has a receiver or administrator appointed to the whole or any part of its assets or if an order shall be made or a resolution passed for its winding up unless such order or resolution is part of a scheme for its amalgamation or
reconstruction (the “Insolvent Party”), the other PARTY shall have the right, at its sole discretion, to serve immediate notice of termination (with the sole exception of the circumstances expounded in 9.5.2.2) of this Agreement,
effective upon receipt. 

  

	9.4.	 Termination by COMPANY. COMPANY may terminate this Agreement at any time by giving [***] written notice
to SELEXIS. 

  

	9.5.	 Consequences of Expiration or Termination. 

 

	 	9.5.1.	 Termination of Licenses. In the event of a termination of this Agreement by COMPANY pursuant to Article
9.2 or 9.4, all and any rights and licenses granted under this Agreement shall terminate upon termination of this Agreement except for the licenses which have become perpetual pursuant to Article 3.1.3. 

In the event of a termination of this Agreement by SELEXIS pursuant to Article 9.2 or 9.3, all and any rights and licenses granted under this
Agreement shall terminate upon termination of this Agreement except for the licenses which have become perpetual pursuant to Article 3.1.3. 
  

	 	9.5.2.	 SELEXIS Technology and Confidential Information. 

 

	 	9.5.2.1	 Subject to the provisions of Article 9.5.2.2, upon termination of this Agreement under Article 9.2 or Article
9.3 where COMPANY is the Insolvent Party, or Article 9.4, COMPANY shall dispose of all tangible embodiments of the SELEXIS Technology and SELEXIS Confidential Information, including without limitation the SELEXIS Materials and Cell Lines, and render
inaccessible or useless all electronic embodiments, of SELEXIS Confidential Information provided to COMPANY by SELEXIS hereunder, except that COMPANY may retain one copy of the SELEXIS Confidential Information delivered hereunder in its secured
legal files only for ensuring compliance with the terms of this Agreement. 

  

	 	9.5.2.2	 Where the COMPANY is the Insolvent Party, SELEXIS acknowledges that this Agreement and the Commercial License
may constitute a material asset of the COMPANY and as such the continuation of this Agreement (and the exercise of the Commercial License) may be of benefit to both Parties, in particular where the Commercial License has been sublicensed. As such,
SELEXIS agrees to provide COMPANY or the COMPANY’S receiver or administrator the opportunity to make submissions for maintenance or restructure of the Agreement. Any submissions must be received by SELEXIS within [***] of the COMPANY

  

					
	Date: October 28, 2013	 	20 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	
entering into insolvency, receivership or administration. SELEXIS agrees to take into consideration any such submissions received within the [***] period before making any decision to terminate
the Agreement under Article 9.3. If no submissions are received within the [***] period or alternatively after due consideration of any submissions, SELEXIS shall have the right, at its sole discretion, to serve immediate notice of termination of
this Agreement under 9.3 and the COMPANY shall dispose of all tangible embodiments in accordance with 9.5.2.1. 

  

	 	9.5.3.	 COMPANY Confidential Information. Upon any expiration or termination of this Agreement, SELEXIS shall
dispose of all tangible embodiments, and render inaccessible or useless all electronic embodiments, of COMPANY Confidential Information provided to SELEXIS by COMPANY hereunder, except that SELEXIS may retain one copy of the COMPANY Confidential
Information delivered hereunder in its secured legal files only for ensuring compliance with the terms of this Agreement. 

  

	 	9.5.4.	 Accrued Obligations. Expiration or termination of this Agreement shall not relieve the PARTIES of any
obligation or liability accruing prior to such expiration or termination. 

  

	10.	 Miscellaneous 

 

	10.1.	 Assignment. Neither this Agreement nor any interest hereunder shall be assignable by either PARTY
without the prior written consent of the other PARTY; provided, that either PARTY may assign this Agreement and all of its rights and obligations hereunder, without such prior written consent, to an entity which acquires all or substantially all of
the business or assets of such PARTY (or the business or assets to which this Agreement pertains) whether by merger, consolidation, reorganization, acquisition, sale or otherwise; and COMPANY may assign this Agreement and all of its rights and
obligations hereunder, without such consent, to an Affiliate if COMPANY remains liable and responsible for the performance and observance of all of the Affiliate’s duties and obligations hereunder, and provided that [***]. This Agreement shall
be binding upon the successors and permitted assigns of the PARTIES and the name of a PARTY appearing herein shall be deemed to include the names of such PARTY’s successors and permitted assigns to the extent necessary to carry out the intent
of this Agreement. Any assignment not in accordance with this Article 10.1 shall be null and void. 

  

	10.2.	 Compliance with Governmental Obligations. Each PARTY shall comply, upon reasonable notice from the other
PARTY, with all governmental requests directed to either PARTY relating to this Agreement and provide all information and assistance necessary to comply with the governmental requests. 

  

					
	Date: October 28, 2013	 	21 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	10.3.	 Counterparts. This Agreement may be executed in any number of counterparts, each of which need not
contain the signature of more than one PARTY but all such counterparts taken together shall constitute one and the same agreement, and may be executed through the use of facsimiles. 

 

	10.4.	 Dispute Resolution. The PARTIES agree that in the event of a dispute between them arising from,
concerning or in any way relating to this Agreement, the PARTIES shall undertake good faith efforts to resolve any such dispute, with the matter being referred at the request of either PARTY to the General Counsel (or chief legal officer) of each
PARTY and, if remaining unresolved after [***], then to the Chief Executive Officers of each PARTY (or their designees). If after [***] of the matter first being referred to the General Counsel the PARTIES are unable to resolve such dispute, either
PARTY may seek any remedy available pursuant to Article 10.16. 

  

	10.5.	 Entire Agreement. This Agreement sets forth all of the covenants, promises, agreements, representations,
warranties, conditions and understandings between the PARTIES with respect to the subject matter hereof, and constitutes and contains the complete, final, and exclusive understanding and agreement of the PARTIES with respect to the subject matter
hereof, and cancels, supersedes and terminates all prior agreements and understanding between the PARTIES with respect to the subject matter hereof. There are no covenants, promises, agreements, representations, warranties, conditions or
understandings, whether oral or written, between the PARTIES other than as set forth herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the PARTIES hereto unless reduced to writing and signed by
the respective authorized officers of the PARTIES. For the avoidance of doubt, to the extent of any inconsistency between this Agreement and the Services Agreement, the terms of this Agreement shall govern and prevail. 

 

	10.6.	 Force Majeure. Neither PARTY shall be liable to the other for loss, damages, default or delay due to
Force Majeure, provided that the PARTY affected by a case of Force Majeure gives prompt notice of such case to the other PARTY. The PARTY giving such notice shall thereupon be excused from its obligations hereunder as it is thereby disabled from
performing for so long as it is so disabled, provided, however, that such affected PARTY commences and continues to take reasonable and diligent actions to cure such cause; and provided further that if any Force Majeure delays or prevents the
performance of the obligations of either PARTY for a continuous period in excess of [***], the PARTY not affected shall then be [***] written notice to the affected PARTY. [***]. 

 

	10.7.	 Further Actions. Each PARTY agrees to execute, acknowledge and deliver such further instruments, and to
do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

  

					
	Date: October 28, 2013	 	22 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	10.8.	 Independent Contractors. The relationship between SELEXIS and COMPANY created by this Agreement is one
of independent contractors and neither PARTY shall have the power or authority to bind or obligate the other PARTY except as expressly set forth in this Agreement. 

 

	10.9.	 Interpretation of Agreement. Articles and other descriptive headings used in this Agreement are for
reference purposes only and shall not constitute a part hereof or affect the meaning or interpretation of this Agreement. Whenever the context so requires, the use of the singular shall be deemed to include the plural and vice versa.

  

	10.10.	 License Obligations. Nothing in this Agreement imposes any obligation upon a PARTY to enter into any
other license or agreement with the other PARTY. 

  

	10.11.	 Notices. All notices and other communications required by this Agreement shall be in writing in the
English language and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier service, to the
PARTIES at the following addresses (or at such other addresses that a PARTY specifies by like notice, provided, however, that notices of a change of address shall be effective only upon written receipt thereof): 

 

					
		 	If to COMPANY, addressed to:
		 	OPTHEA PTY LTD
		
		 	Level 4, 650 Chapel Street
		 	South Yarra	  	
		 	VIC 3141	  	
		 	Australia	  	
		 	Attention:	  	CEO
		 	Facsimile:	  	[***]

  

					
		 	If to SELEXIS, addressed to:
			
	 	 	 	  	Selexis S.A.
	 	 	 	  	[***]
			
		 	Attention:	  	[***]
		 	With a copy to:	  	[***]
		 	Facsimile:	  	[***]

  

  

					
	Date: October 28, 2013	 	23 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	10.12.	 Binding Effect. This Agreement shall be binding upon and inure solely to the benefit of COMPANY and
SELEXIS (and their permitted successors and assigns) and nothing in this Agreement (express or implied) is intended to or shall confer upon any Third Party any rights, benefits or remedies of any nature whatsoever under or by reason of this
Agreement. 

  

	10.13.	 Severability. If any term, covenant or condition of this Agreement or the application thereof to any
PARTY or circumstance shall, to any extent, be held to be invalid or unenforceable, then the remainder of this Agreement, or the application of such term, covenant or condition to PARTIES or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each term, covenant or condition of this Agreement shall be valid and be enforced to the fullest extent permitted by applicable law. 

 

	10.14.	 Waiver. The failure on the part of a PARTY to exercise or enforce any rights conferred upon it hereunder
shall not be deemed to be a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times hereafter. 

  

	10.15.	 Survival. Articles 1, 3.4, 4, 5, 6, 7, 8, 9.5 and 10 shall survive any termination or expiration of this
Agreement in accordance with their terms. 

  

	10.16.	 Governing Law and Jurisdiction. This Agreement shall be governed by and construed in accordance with the
substantive laws of [***], without regard to principles of conflict of laws. Any dispute arising out of or in connection with this Agreement shall be subject to the exclusive jurisdiction of the courts of [***]. 

  

					
	Date: October 28, 2013	 	24 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

 IN WITNESS WHEREOF, the PARTIES, having read the terms of this
Agreement and intending to be legally bound hereby, do hereby execute this Agreement: 
  

									
	SELEXIS SA	 		 	OPTHEA PTY LTD
					
	Signature:	 	/s/ Girod PA	 		 	Signature:	 	/s/ Megan Baldwin
					
	Place, Date:	 	 Plan-les-Ouates, Nov 15, 2013
	 		 	Place, Date:	 	Melbourne, 7 Nov 2013
			
	Name: Girod PA	 		 	Name: Megan Baldwin
			
	Title: Chief Scientific Officier	 		 	Title: CEO, Opthea P/L
		 		 	
					
		 		 		 		 	
					
	Signature:	 	/s/ Regine Brokamp	 		 	Signature:	 	/s/ Robert Klupacs
					
	Place, Date:	 	 PLO, Nov 15th 2013
	 		 	Place, Date:	 	Melbourne, 7 Nov 2013
			
	Name: Regine Brokamp	 		 	Name: Robert Klupacs
			
	Title: COO	 		 	Title: Director, Opthea Pty Limited

  

					
		 	25 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

 EXHIBIT 1 

SELEXIS PATENT RIGHTS 
 Patent 1. 

 

			
	 Title
	  	[***]
		
	 Filing date
	  	[***]
		
	 Application Number
	  	[***]
		
	 Grant Patent Number
	  	[***]
		
	 Geographies
	  	[***]
		
	 Status
	  	[***]

 Patent 2. 
  

			
	 Title
	  	[***]
		
	 Filing date
	  	[***]
		
	 Application Number
	  	[***]
		
	 Publication Number
	  	[***]
		
	 Geographies
	  	[***]

  

					
	Date: October 28, 2013	 	26 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

 EXHIBIT 2 

LICENSED PRODUCTS 
 Vascular Endothelial Growth Factor Receptor 3
soluble proteins 

  

					
	Date: October 28, 2013	 	27 of 27	 	Opthea
		 	Selexis SA

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]